DeCure for Familial hemophagocytic lymphohistiocytosis type 1
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for familial hemophagocytic lymphohistiocytosis type 1 — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFamilial hemophagocytic lymphohistiocytosis type 1 maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for familial hemophagocytic lymphohistiocytosis type 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Familial hemophagocytic lymphohistiocytosis is a rare haematologic disorder driven by dysregulated immune activation and carries a high rate of mortality. The 2022 case study reports one case of familial HLH, correlating clinical history, family history, bone marrow findings and genetic tests, but provides no survival data, no response rates, and no sample size beyond a single patient. The authors call for greater awareness among clinicians and pathologists for early diagnosis and better survival, but the abstract itself does not demonstrate that early diagnosis improves outcomes in any measured way.
A 2016 case report describes a patient with haemophagocytic lymphohistiocytosis secondary to a T-cell rich B-cell lymphoma, not familial HLH. That patient was treated with conventional chemotherapy and achieved complete remission. The abstract concludes that prompt aetiologic diagnosis and treatment leads to satisfactory outcome, but again offers no numbers — no survival time, no response rate, no sample size. This case is not directly applicable to familial HLH type 1, as the underlying cause is a lymphoma, not a genetic defect.
No drug is mentioned in either abstract for the treatment of familial HLH type 1. The 2016 report uses conventional chemotherapy for a secondary, lymphoma-driven HLH, but that regimen is not specified and cannot be extrapolated to the familial form. The 2022 familial HLH case study does not describe any treatment or drug.
What is still missing: prospective trials enrolling patients with genetically confirmed familial HLH type 1, standardised treatment protocols, and any data linking specific drugs to survival or remission in this subtype. Without patient stratification by genetic mutation and adequately powered studies, no drug can be recommended.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BMC Hematology · 2016 · 6 citations · open access
Hemophagocytic lymphohistiocytosis complicating a T-cell rich B-cell lymphoma
AbstractBACKGROUND: Hemophagocytic lymphohistiocytosis in adults is often secundary to an infection or a neoplasm. In this last case, T cell lymphomas are the most frequent causes. Hemophagocytic lymphohistiocytosis secundary to a B cell lymphoma has been rarely reported. CASE PRESENTATION: We describe a case of a hemophagocytic lymphohistiocytosis complicating a T-cell rich B-cell lymphoma treated with conventionnal chemotherapy leading to a complete remission. CONCLUSION: Prompt etiologic diagnosis and treatment of hemophagocytic lymphohistiocytosis leads to satisfactory outcome.
Zenodo (CERN European Organization for Nuclear Research) · 2022 · 0 citations · open access
A Hematopathology Case Study of Familial Hemophagocytic Lymphohistiocytosis (HLH)
AbstractHemophagocytic lymphohistiocytosis is a rare hematologic disorder caused by dysregulated immune activation and carries a high rate of mortality. It is categorized broadly into Primary (Familial ) and secondary types. The recent classification of histiocytoses by Histiocytic society has placed Hemophagocytic lymphohistiocytosis in the “H” group. Greater awareness of Familial hemophagocytic lymphohistiocytosis is required among clinicians and pathologists for early diagnosis and a better survival. Here we report a case of Familial hemophagocytic lymphohistiocytosis correlating with clinical history, family history, bone marrow findings and genetic tests.
Zenodo (CERN European Organization for Nuclear Research) · 2022 · 0 citations · open access
A Hematopathology Case Study of Familial Hemophagocytic Lymphohistiocytosis (HLH)
AbstractHemophagocytic lymphohistiocytosis is a rare hematologic disorder caused by dysregulated immune activation and carries a high rate of mortality. It is categorized broadly into Primary (Familial ) and secondary types. The recent classification of histiocytoses by Histiocytic society has placed Hemophagocytic lymphohistiocytosis in the “H” group. Greater awareness of Familial hemophagocytic lymphohistiocytosis is required among clinicians and pathologists for early diagnosis and a better survival. Here we report a case of Familial hemophagocytic lymphohistiocytosis correlating with clinical history, family history, bone marrow findings and genetic tests.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
